iShares Biotechnology ETF
608 hedge funds and large institutions have $5.68B invested in iShares Biotechnology ETF in 2018 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 204 increasing their positions, 227 reducing their positions, and 77 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
608
Holders Change
-16
Holders Change %
-2.56%
% of All Funds
13.95%
Holding in Top 10
25
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-16.67%
% of All Funds
0.57%
New
66
Increased
204
Reduced
227
Closed
77
Calls
$377M
Puts
$657M
Net Calls
-$280M
Net Calls Change
+$432M
Top Buyers
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$447M |
| 2 |
N
Natixis
Paris,
France
|
+$106M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$43.4M |
| 4 |
JG
Jefferies Group
New York
|
+$36.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$28.6M |
Top Sellers
| 1 |
CM
Churchill Management
Los Angeles,
California
|
-$192M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$125M |
| 3 |
Goldman Sachs
New York
|
-$66.8M |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$45.9M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$42.1M |